Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetes

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 384 KB, PDF document

  • Pamela Bowman
  • Kashyap A. Patel
  • Timothy J. McDonald
  • Holst, Jens Juul
  • Hartmann, Bolette
  • Maria Leveridge
  • Beverley M. Shields
  • Suzie Hammersley
  • Steve R. Spaull
  • Bridget A. Knight
  • Sarah E. Flanagan
  • Maggie H. Shepherd
  • Rob C. Andrews
  • Andrew T. Hattersley

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (SU)-treated KCNJ11 permanent neonatal diabetes. The aim of this study was to assess for the first time the incretin hormone response to carbohydrate and protein/fat in adults with sulfonylurea-treated KCNJ11 permanent neonatal diabetes compared with that of controls without diabetes. Participants were given a breakfast high in carbohydrate and an isocaloric breakfast high in protein/fat on two different mornings. Incremental area under the curve and total area under the curve (0-240 minutes) for total GLP-1 and GIP were compared between groups, using non-parametric statistical methods. Post-meal GLP-1 and GIP secretion were similar in cases and controls, suggesting this process is adenosine triphosphate-sensitive potassium channel-independent. Future research will investigate whether treatments targeting the incretin pathway are effective in individuals with KCNJ11 permanent neonatal diabetes who do not have good glycemic control on sulfonylurea alone.

Original languageEnglish
JournalJournal of Diabetes Investigation
Issue number12
Pages (from-to)1378-1382
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

    Research areas

  • GIP, GLP-1, incretin hormones, Neonatal diabetes, sulfonylurea

ID: 371567165